119 related articles for article (PubMed ID: 26854433)
1. Bladder cancer risk from the perspective of genetic polymorphisms in the carcinogen metabolizing enzymes.
Antonova O; Toncheva D; Grigorov E
J BUON; 2015; 20(6):1397-406. PubMed ID: 26854433
[TBL] [Abstract][Full Text] [Related]
2. GST, NAT, SULT1A1, CYP1B1 genetic polymorphisms, interactions with environmental exposures and bladder cancer risk in a high-risk population.
Hung RJ; Boffetta P; Brennan P; Malaveille C; Hautefeuille A; Donato F; Gelatti U; Spaliviero M; Placidi D; Carta A; Scotto di Carlo A; Porru S
Int J Cancer; 2004 Jul; 110(4):598-604. PubMed ID: 15122594
[TBL] [Abstract][Full Text] [Related]
3. Combined effect of smoking and inherited polymorphisms in arylamine N-acetyltransferase 2, glutathione S-transferases M1 and T1 on bladder cancer in a Tunisian population.
Rouissi K; Ouerhani S; Marrakchi R; Ben Slama MR; Sfaxi M; Ayed M; Chebil M; El Gaaied AB
Cancer Genet Cytogenet; 2009 Apr; 190(2):101-7. PubMed ID: 19380028
[TBL] [Abstract][Full Text] [Related]
4. Polymorphisms of N-acetyltransferases, glutathione S-transferases, microsomal epoxide hydrolase and sulfotransferases: influence on cancer susceptibility.
Hengstler JG; Arand M; Herrero ME; Oesch F
Recent Results Cancer Res; 1998; 154():47-85. PubMed ID: 10026993
[TBL] [Abstract][Full Text] [Related]
5. GSTA1, GSTM1, GSTP1, and GSTT1 polymorphisms and susceptibility to smoking-related bladder cancer: a case-control study.
Matic M; Pekmezovic T; Djukic T; Mimic-Oka J; Dragicevic D; Krivic B; Suvakov S; Savic-Radojevic A; Pljesa-Ercegovac M; Tulic C; Coric V; Simic T
Urol Oncol; 2013 Oct; 31(7):1184-92. PubMed ID: 24075358
[TBL] [Abstract][Full Text] [Related]
6. Association of genetic polymorphism of glutathione S-transferase (GSTM1, GSTT1, GSTP1) with bladder cancer susceptibility.
Safarinejad MR; Safarinejad S; Shafiei N; Safarinejad S
Urol Oncol; 2013 Oct; 31(7):1193-203. PubMed ID: 22154357
[TBL] [Abstract][Full Text] [Related]
7. Markers of genetic susceptibility in human environmental hygiene and toxicology: the role of selected CYP, NAT and GST genes.
Thier R; Brüning T; Roos PH; Rihs HP; Golka K; Ko Y; Bolt HM
Int J Hyg Environ Health; 2003 Jun; 206(3):149-71. PubMed ID: 12872524
[TBL] [Abstract][Full Text] [Related]
8. Cancer and molecular biomarkers of phase 2.
Dalhoff K; Buus Jensen K; Enghusen Poulsen H
Methods Enzymol; 2005; 400():618-27. PubMed ID: 16399374
[TBL] [Abstract][Full Text] [Related]
9. p53 mutations in bladder cancer: evidence for exogenous versus endogenous risk factors.
Schroeder JC; Conway K; Li Y; Mistry K; Bell DA; Taylor JA
Cancer Res; 2003 Nov; 63(21):7530-8. PubMed ID: 14612556
[TBL] [Abstract][Full Text] [Related]
10. Smoking and polymorphisms in xenobiotic metabolism and DNA repair genes are additive risk factors affecting bladder cancer in Northern Tunisia.
Rouissi K; Ouerhani S; Hamrita B; Bougatef K; Marrakchi R; Cherif M; Ben Slama MR; Bouzouita M; Chebil M; Ben Ammar Elgaaied A
Pathol Oncol Res; 2011 Dec; 17(4):879-86. PubMed ID: 21647780
[TBL] [Abstract][Full Text] [Related]
11. Genetic polymorphism of glutathione S-transferases M1 and T1 as a risk factor in lung and bladder cancers.
Salagovic J; Kalina I; Stubna J; Habalová V; Hrivnák M; Valanský L; Kohút A; Biros E
Neoplasma; 1998; 45(5):312-7. PubMed ID: 9921921
[TBL] [Abstract][Full Text] [Related]
12. Polymorphic deletions of the GSTT1 and GSTM1 genes and susceptibility to bladder cancer.
Salinas-Sánchez AS; Sánchez-Sánchez F; Donate-Moreno MJ; Rubio-del-Campo A; Gimenez-Bachs JM; Lorenzo-Romero JG; Serrano-Oviedo L; Escribano J
BJU Int; 2011 Jun; 107(11):1825-32. PubMed ID: 20942828
[TBL] [Abstract][Full Text] [Related]
13. Arylamine N-acetyltransferase 1 (NAT1) and 2 (NAT2) polymorphisms in susceptibility to bladder cancer: the influence of smoking.
Okkels H; Sigsgaard T; Wolf H; Autrup H
Cancer Epidemiol Biomarkers Prev; 1997 Apr; 6(4):225-31. PubMed ID: 9107426
[TBL] [Abstract][Full Text] [Related]
14. Combined analysis of inherited polymorphisms in arylamine N-acetyltransferase 2, glutathione S-transferases M1 and T1, microsomal epoxide hydrolase, and cytochrome P450 enzymes as modulators of bladder cancer risk.
Brockmöller J; Cascorbi I; Kerb R; Roots I
Cancer Res; 1996 Sep; 56(17):3915-25. PubMed ID: 8752158
[TBL] [Abstract][Full Text] [Related]
15. Cytochrome P-450 and acetyltransferase expression as biomarkers of carcinogen-DNA adduct levels and human cancer susceptibility.
Badawi AF; Stern SJ; Lang NP; Kadlubar FF
Prog Clin Biol Res; 1996; 395():109-40. PubMed ID: 8895986
[TBL] [Abstract][Full Text] [Related]
16. Polymorphisms of glutathione-S-transferase and arylamine N-acetyltransferase enzymes and susceptibility to colorectal cancer.
Kiss I; Németh A; Bogner B; Pajkos G; Orsós Z; Sándor J; Csejtey A; Faluhelyi Z; Rodler I; Ember I
Anticancer Res; 2004; 24(6):3965-70. PubMed ID: 15736440
[TBL] [Abstract][Full Text] [Related]
17. [Genetic polymorphisms in xenobiotic metabolizing enzymes as a determinant of susceptibility to environmental mutagens and carcinogens in humans].
Ozawa S
Yakugaku Zasshi; 1997 Nov; 117(10-11):895-909. PubMed ID: 9414599
[TBL] [Abstract][Full Text] [Related]
18. Gender, smoking, glutathione-S-transferase variants and bladder cancer incidence: a population-based study.
Karagas MR; Park S; Warren A; Hamilton J; Nelson HH; Mott LA; Kelsey KT
Cancer Lett; 2005 Feb; 219(1):63-9. PubMed ID: 15694665
[TBL] [Abstract][Full Text] [Related]
19. Dietary isothiocyanates, GSTM1, GSTT1, NAT2 polymorphisms and bladder cancer risk.
Zhao H; Lin J; Grossman HB; Hernandez LM; Dinney CP; Wu X
Int J Cancer; 2007 May; 120(10):2208-13. PubMed ID: 17290402
[TBL] [Abstract][Full Text] [Related]
20. Polymorphisms of N-acetyltransferase 2, glutathione S-transferase mu and theta genes as risk factors of bladder cancer in relation to asthma and tuberculosis.
Kim WJ; Lee HL; Lee SC; Kim YT; Kim H
J Urol; 2000 Jul; 164(1):209-13. PubMed ID: 10840461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
